New approach for cholesterol and sphingolipid reduction in Niemann-Pick C1 disease
降低尼曼-匹克 C1 病胆固醇和鞘脂的新方法
基本信息
- 批准号:10078545
- 负责人:
- 金额:$ 16.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-25 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgreementAutophagocytosisBehavioral SymptomsBindingBrainCRISPR/Cas technologyCatabolismCellsCerebellumChildChildhoodCholesterolClinical TrialsCognitionCombined Modality TherapyComplexDataDefectDevelopmentDiseaseDisease ProgressionDoseEnzymesEpigenetic ProcessFibroblastsFunctional disorderGenesGoalsHistone DeacetylaseHistone Deacetylase InhibitorHomeostasisHumanKnowledgeLife ExtensionLife Support CareLipidsLiverLongevityLysosomesMediatingMediator of activation proteinMembraneMemoryMentorsMetabolic PathwayMetabolismMolecularMolecular GeneticsMonitorMotor SkillsMovementMusMutant Strains MiceMutationNPC1 geneNational Institute of Child Health and Human DevelopmentNerve DegenerationNeurologicNuclearPathogenesisPathogenicityPathologyPatientsPharmacologyPhasePhenotypePlayProcessProteinsPublishingRegulationResearchRoleSPHK1 enzymeSphingolipidsSphingosineSupraoptic Vertical OphthalmoplegiaSystemTechniquesTherapeuticTrainingWorkbasecholesterol traffickingcitrate carrierclinically relevantdisease-causing mutationeffective therapyhuman diseaseimproved outcomein vivoinnovationlate endosomeliver functionmouse modelmultiple sclerosis treatmentmutantmutant mouse modelneuroinflammationneuropathologynovelnovel strategiesnovel therapeutic interventionoverexpressionprogramsprogressive neurodegenerationrestorationsphingosine 1-phosphatesphingosine kinasetargeted treatmenttherapeutic evaluationtraffickingtreatment strategy
项目摘要
Niemann-Pick Type C (NPC) is fatal lipid storage disease caused by mutations in NPC1 (95%) and NPC2 (5%)
genes. NPC is characterized by cholesterol and sphingolipid accumulation, complex progressive
neurodegeneration, and a lifespan of less than 20 years. NPC1/2 function in late endosomes/lysosomes
(LE/L), with soluble NPC2 binding unesterified cholesterol and transferring it to integral membrane NPC1 that
facilitates its movement out of the LE/L. Recently it was discovered that HDAC inhibition can epigenetically
increase expression of the low activity NPC1mut protein to levels that can correct the cholesterol defect.
However, HDAC inhibitors now being tried for treatment NPC do not get into the CNS and do not treat the
neurological sequelea of NPC. My published results, however, suggest that FTY720/Fingolimod, used for
treatment of multiple sclerosis, is also a HDAC inhibitor that increases expression of NPC1/2 and corrects
cholesterol and sphingolipid storage defects in NPC1mut fibroblasts. Furthermore, my preliminary data in mice
show that FTY720 does accumulate in the cerebellum, increases NPC1/2 expression in brain as well as liver,
and reduces cholesterol levels. Hence, in my first Aim, I will extend this approach to an in vivo mouse model of
NPC that more accurately mimics the human disorder, monitoring brain and liver NPC1/2 expression,
cholesterol and sphingolipid homeostasis, and disease progression. While accumulation of sphingolipids have
been implicated in development of NPC-associated neurological defects, the mechanisms remain unknown.
Recent published work and my preliminary data support the premise that a deficiency of sphingosine kinase 1
(SphK1), which converts the sphingolipid metabolite sphingosine to the bioactive mediator sphingosine-1-
phosphate, may be important in pathogenesis of NPC. Consequently, my Aim 2a focuses on the role of SphK1
in sphingolipid accumulation on a cellular level through a detailed examination of its expression, localization,
and regulation in NPC mutant fibroblasts. Furthermore, by employing a novel SphK1 activator we recently
discovered, and CRISPR CAS9 mediated modulation of SphK1 expression and activity, I will examine whether
increasing sphingolipid catabolism suppresses the NPC cellular phenotype. Finally, most therapeutic
approaches focus on reducing cholesterol accumulation, but our preliminary data suggest that cholesterol and
sphingolipid metabolic pathways are interdependent, decreased SphK1 activity leads to accumulation of both
sphingolipids and cholesterol. Therefore, I will examine the benefits of targeting both cholesterol and
sphingolipid accumulation through a novel “dual lipid” reduction strategy in a mouse model of NPC. I expect
that my results will validate the use of FTY720/Fingolimod to effectively restore normal NPC1/2 activity levels,
answer longstanding questions about the mechanism of sphingolipid accumulation in NPC, and pave the way
for a new therapeutic strategy targeting both pathogenic classes of lipids in NPC disease.
Niemann-Pick C型(NPC)是由NPC1(95%)和NPC2(5%)突变引起的致死性脂质沉积病
基因。鼻咽癌的特点是胆固醇和鞘脂蓄积,复杂进行性
神经退化,寿命不到20年。NPC1/2在晚期内小体/溶酶体中的作用
(LE/L),与可溶性NPC2结合未酯化胆固醇并将其转移到完整的膜NPC1上,NPC1
促进其走出LE/L。最近发现,HDAC抑制可以在表观遗传上
将低活性NPC1mut蛋白的表达提高到可以纠正胆固醇缺陷的水平。
然而,目前正在尝试用于治疗鼻咽癌的HDAC抑制剂不能进入中枢系统,也不能治疗鼻咽癌
鼻咽癌的神经后遗症。然而,我发表的结果表明,FTY720/Fingolimod用于
治疗多发性硬化症,也是一种HDAC抑制剂,增加NPC1/2的表达并纠正
NPC1mut成纤维细胞中胆固醇和鞘磷脂储存缺陷。此外,我在小鼠身上的初步数据
表明FTY720确实在小脑中蓄积,增加NPC1/2在脑和肝脏中的表达,
并降低胆固醇水平。因此,在我的第一个目标中,我将把这种方法扩展到活体小鼠模型
NPC更准确地模拟了人类的疾病,监测大脑和肝脏NPC1/2的表达,
胆固醇和鞘脂的动态平衡,以及疾病的进展。而神经鞘脂类的积累
虽然与鼻咽癌相关神经缺陷的发生有关,但其机制尚不清楚。
最近发表的研究和我的初步数据支持这样一个假设,即鞘氨醇激酶1的缺陷
(SphK1),它将鞘磷脂代谢物鞘氨醇转化为生物活性介体鞘氨醇-1-
磷酸盐可能在鼻咽癌的发病机制中起重要作用。因此,我的目标2a集中在SphK1的作用上
通过详细研究其表达,定位,
以及对鼻咽癌突变成纤维细胞的调控。此外,通过使用一种新的SphK1激活剂,我们最近
发现,并且CRISPR Cas9介导了SphK1的表达和活性的调节,我将检查是否
鞘磷脂分解代谢增加会抑制鼻咽癌细胞的表型。最后,最有疗效的
方法的重点是减少胆固醇的积累,但我们的初步数据表明,胆固醇和
鞘磷脂的代谢途径是相互依赖的,SphK1活性降低会导致两者的积累
鞘脂和胆固醇。因此,我将研究同时针对胆固醇和
在鼻咽癌小鼠模型中,神经鞘脂脂通过一种新的“双脂”减少策略积累。我希望
我的结果将验证使用FTY720/Fingolimod有效地恢复正常的NPC1/2活动水平,
回答长期以来关于神经鞘脂脂在鼻咽癌中积累机制的问题,并为
寻找一种针对鼻咽癌疾病两种病原性血脂的新治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jason Charles Newton其他文献
Jason Charles Newton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jason Charles Newton', 18)}}的其他基金
New approach for cholesterol and sphingolipid reduction in Niemann-Pick C1 disease
降低尼曼-匹克 C1 病胆固醇和鞘脂的新方法
- 批准号:
10074870 - 财政年份:2019
- 资助金额:
$ 16.55万 - 项目类别:
New approach for cholesterol and sphingolipid reduction in Niemann-Pick C1 disease
降低尼曼-匹克 C1 病胆固醇和鞘脂的新方法
- 批准号:
10312032 - 财政年份:2019
- 资助金额:
$ 16.55万 - 项目类别:
New approach for cholesterol and sphingolipid reduction in Niemann-Pick C1 disease
降低尼曼-匹克 C1 病胆固醇和鞘脂的新方法
- 批准号:
9762961 - 财政年份:2018
- 资助金额:
$ 16.55万 - 项目类别:
相似海外基金
A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
- 批准号:
22KJ0334 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Grant-in-Aid for JSPS Fellows
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
- 批准号:
2410236 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
- 批准号:
23K18762 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
- 批准号:
900240 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Collaborative R&D
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
- 批准号:
23H00770 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
- 批准号:
10829529 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
- 批准号:
2346114 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
- 批准号:
10828588 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
- 批准号:
MR/X029301/1 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Linguistic transfer in a contact variety of Spanish: Gender agreement production and attitudes
博士论文研究:西班牙语接触变体中的语言迁移:性别协议的产生和态度
- 批准号:
2234506 - 财政年份:2023
- 资助金额:
$ 16.55万 - 项目类别:
Standard Grant